Northwest Biotherapeutics (LTS:0K95) Debt-to-Equity : -0.67 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Northwest Biotherapeutics Debt-to-Equity?

Northwest Biotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was £27.13 Mil. Northwest Biotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was £11.49 Mil. Northwest Biotherapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was £-57.67 Mil. Northwest Biotherapeutics's debt to equity for the quarter that ended in Mar. 2024 was -0.67.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Northwest Biotherapeutics's Debt-to-Equity or its related term are showing as below:

LTS:0K95' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.68 Med: -0.46 Max: -0.04
Current: -0.67

During the past 13 years, the highest Debt-to-Equity Ratio of Northwest Biotherapeutics was -0.04. The lowest was -4.68. And the median was -0.46.

LTS:0K95's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs LTS:0K95: -0.67

Northwest Biotherapeutics Debt-to-Equity Historical Data

The historical data trend for Northwest Biotherapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics Debt-to-Equity Chart

Northwest Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.40

-0.06

-0.31

-0.21

-0.69

Northwest Biotherapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															-0.56	-0.50	-0.58	-0.69	-0.67

Competitive Comparison of Northwest Biotherapeutics's Debt-to-Equity

For the Biotechnology subindustry, Northwest Biotherapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Northwest Biotherapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's Debt-to-Equity falls into.

Northwest Biotherapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Northwest Biotherapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(16.427	+	19.565)	/	-51.961
	=	-0.69

Northwest Biotherapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(27.134	+	11.489)	/	-57.673
	=	-0.67

Northwest Biotherapeutics (LTS:0K95) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Northwest Biotherapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Northwest Biotherapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Northwest Biotherapeutics (LTS:0K95) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (LTS:0K95) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

NWBO:USA NBYB:Germany

Address

4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814

Website

https://www.nwbio.com

Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.

Northwest Biotherapeutics (LTS:0K95) Headlines

No Headlines